Literature DB >> 21920335

MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course.

Xue-Qiao Zhao1, Li Dong, Tom Hatsukami, Binh An Phan, Baocheng Chu, Andrew Moore, Trevor Lane, Moni B Neradilek, Nayak Polissar, Duane Monick, Colin Lee, Hunter Underhill, Chun Yuan.   

Abstract

OBJECTIVES: The purpose of this study was to test the lipid depletion hypothesis and to establish the time course of change in carotid plaque morphology and composition during lipid therapy using high-resolution magnetic resonance imaging (MRI).
BACKGROUND: Lipid therapy is thought to improve plaque stability and reduce cardiovascular events by targeting the plaque rupture risk features such as large lipid core, thin fibrous cap, and high level of inflammatory infiltrates. However, the plaque stabilizing process during lipid therapy has not been clearly demonstrated in humans and in vivo.
METHODS: Subjects with coronary or carotid artery disease, apolipoprotein B ≥120 mg/dl, and lipid treatment history <1 year, were randomly assigned to atorvastatin monotherapy or to atorvastatin-based combination therapies with appropriate placebos for 3 years. All subjects underwent high-resolution, multicontrast bilateral carotid MRI scans at baseline and annually for 3 years. All images were analyzed for quantification of wall area and plaque composition blinded to therapy, laboratory results, and clinical course.
RESULTS: After 3 years of lipid therapy, the 33 subjects with measurable lipid-rich necrotic core (LRNC) at baseline had a significant reduction in plaque lipid content: LRNC volume decreased from 60.4 ± 59.5 mm(3) to 37.4 ± 69.5 mm(3) (p < 0.001) and %LRNC (LRNC area/wall area in the lipid-rich regions) from 14.2 ± 7.0% to 7.4 ± 8.2% (p < 0.001). The time course showed that %LRNC decreased by 3.2 (p < 0.001) in the first year, by 3.0 (p = 0.005) in the second year, and by 0.91 (p = 0.2) in the third year. Changes in LRNC volume followed the same pattern. Percent wall volume (100 × wall/outer wall, a ratio of volumes) in the lipid-rich regions significantly decreased from 52.3 ± 8.5% to 48.6 ± 9.7% (p = 0.002). Slices containing LRNC had significantly more percent wall volume reduction than those without (-4.7% vs. -1.4%, p = 0.02).
CONCLUSIONS: Intensive lipid therapy significantly depletes carotid plaque lipid. Statistically significant plaque lipid depletion is observed after 1 year of treatment and continues in the second year, and precedes plaque regression. (Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications [The CPC Study]; NCT00715273).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920335      PMCID: PMC3638021          DOI: 10.1016/j.jcmg.2011.06.013

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  32 in total

1.  Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study.

Authors:  Xue-Qiao Zhao; Binh An P Phan; Baocheng Chu; Frank Bray; Andrew B Moore; Nayak L Polissar; J Theodore Dodge; Colin D Lee; Thomas S Hatsukami; Chun Yuan
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

2.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

3.  In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology.

Authors:  Jianming Cai; Thomas S Hatsukami; Marina S Ferguson; William S Kerwin; Tobias Saam; Baocheng Chu; Norihide Takaya; Nayak L Polissar; Chun Yuan
Journal:  Circulation       Date:  2005-11-21       Impact factor: 29.690

4.  Surface coil phased arrays for high-resolution imaging of the carotid arteries.

Authors:  C E Hayes; C M Mathis; C Yuan
Journal:  J Magn Reson Imaging       Date:  1996 Jan-Feb       Impact factor: 4.813

5.  Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study.

Authors:  X Q Zhao; C Yuan; T S Hatsukami; E H Frechette; X J Kang; K R Maravilla; B G Brown
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

6.  Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis.

Authors:  D M Small; M G Bond; D Waugh; M Prack; J K Sawyer
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience.

Authors:  Vincent C Cappendijk; Kitty B J M Cleutjens; Alfons G H Kessels; Sylvia Heeneman; Geert Willem H Schurink; Rob J T J Welten; Werner H Mess; Mat J A P Daemen; Jos M A van Engelshoven; M Eline Kooi
Journal:  Radiology       Date:  2005-02       Impact factor: 11.105

8.  Predictors of surface disruption with MR imaging in asymptomatic carotid artery stenosis.

Authors:  H R Underhill; C Yuan; V L Yarnykh; B Chu; M Oikawa; L Dong; N L Polissar; G A Garden; S C Cramer; T S Hatsukami
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-15       Impact factor: 3.825

9.  Magnetic resonance imaging of carotid atherosclerosis: plaque analysis.

Authors:  William Kerwin; Dongxiang Xu; Fei Liu; Tobias Saam; Hunter Underhill; Norihide Takaya; Baocheng Chu; Thomas Hatsukami; Chun Yuan
Journal:  Top Magn Reson Imaging       Date:  2007-10

10.  Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI--initial results.

Authors:  Norihide Takaya; Chun Yuan; Baocheng Chu; Tobias Saam; Hunter Underhill; Jianming Cai; Nam Tran; Nayak L Polissar; Carol Isaac; Marina S Ferguson; Gwenn A Garden; Steven C Cramer; Kenneth R Maravilla; Beverly Hashimoto; Thomas S Hatsukami
Journal:  Stroke       Date:  2006-02-09       Impact factor: 7.914

View more
  49 in total

Review 1.  Atherosclerosis: Making a U Turn.

Authors:  Ira J Goldberg; Gaurav Sharma; Edward A Fisher
Journal:  Annu Rev Med       Date:  2020-01-27       Impact factor: 13.739

Review 2.  Noninvasive Imaging of Atherosclerotic Plaque Progression: Status of Coronary Computed Tomography Angiography.

Authors:  Veit Sandfort; Joao A C Lima; David A Bluemke
Journal:  Circ Cardiovasc Imaging       Date:  2015-07       Impact factor: 7.792

Review 3.  MRI of carotid atherosclerosis.

Authors:  William S Kerwin; Thomas Hatsukami; Chun Yuan; Xue-Qiao Zhao
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

4.  How does lipid lowering prevent coronary events? New insights from human imaging trials.

Authors:  Peter Libby
Journal:  Eur Heart J       Date:  2015-01-08       Impact factor: 29.983

5.  High-resolution MRI assessed carotid atherosclerotic plaque characteristics comparing men and women with elevated ApoB levels.

Authors:  Tianwen Han; Pathmaja Paramsothy; Jaekyoung Hong; Daniel Isquith; Dongxiang Xu; Hua Bai; Moni Neradilek; Edward Gill; Xue-Qiao Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2020-02-04       Impact factor: 2.357

6.  Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH.

Authors:  Jie Sun; Xue-Qiao Zhao; Niranjan Balu; Moni B Neradilek; Daniel A Isquith; Kiyofumi Yamada; Gádor Cantón; John R Crouse; Todd J Anderson; John Huston; Kevin O'Brien; Daniel S Hippe; Nayak L Polissar; Chun Yuan; Thomas S Hatsukami
Journal:  JACC Cardiovasc Imaging       Date:  2017-03

7.  MR imaging-verified plaque delipidation with lipid-lowering therapy important questions remain.

Authors:  Christopher M Kramer; Venkatesh Mani; Zahi A Fayad
Journal:  JACC Cardiovasc Imaging       Date:  2011-09

8.  Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.

Authors:  Binh An P Phan; Luis Muñoz; Pey Shadzi; Daniel Isquith; Michael Triller; B Greg Brown; Xue-Qiao Zhao
Journal:  Am J Cardiol       Date:  2012-11-17       Impact factor: 2.778

9.  Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS).

Authors:  Binh An P Phan; Andrew B Moore; Joseph Davis; Laura J Pollan; Blazej Neradilek; B Greg Brown; Xue-Qiao Zhao
Journal:  J Clin Lipidol       Date:  2014-07-12       Impact factor: 4.766

Review 10.  RNA interference therapy: a new solution for intracranial atherosclerosis?

Authors:  Xiang-Yan Chen; Tao Tang; Ka-Sing Wong
Journal:  Ann Transl Med       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.